JP7229565B2 - メラノーマを治療するための方法 - Google Patents
メラノーマを治療するための方法 Download PDFInfo
- Publication number
- JP7229565B2 JP7229565B2 JP2020550082A JP2020550082A JP7229565B2 JP 7229565 B2 JP7229565 B2 JP 7229565B2 JP 2020550082 A JP2020550082 A JP 2020550082A JP 2020550082 A JP2020550082 A JP 2020550082A JP 7229565 B2 JP7229565 B2 JP 7229565B2
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- tumor
- cells
- dapanthril
- olt1177
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
2.S.Shalapour,et al.J Clin Invest 125,3347-3355(2015)。
3.C.A.Dinarello.Blood 117,3720-3732(2011)。
4.R.N.Apte.et al.Cancer Metastasis Rev 25,387-408(2006)。
5.C.A.Dinarello.Cancer Metastasis Rev 29,317-329(2010)。
6.B.Guo,et al.Sci Rep 6,36107(2016)。
7.D.N.Khalil,et al.Nat Rev Clin Oncol 13,273-290。
8.M.A.Postow,et al.N Engl J Med 378,158-168(2018)。
9.C.Marchetti,et al.Proc Natl Acad Sci USA 115,E1530-1539(2018)。
10.C.R.Millrud,et al.Oncotarget 8,3649-3665(2017)。
11.S.Ostrand-Rosenberg,et al.J Immunol 182,4499-4506(2009)。
12.V.Umansky,et al.Vaccines(Basel)4,E36(2016)。
13.K.R.Jordan et.al.,Cancer Immunol Immunother 62,1711-1722(2013)。
Claims (6)
- ダパンストリル、又はその医薬的に許容可能な溶媒和化合物の有効量を含む、メラノーマを予防する及び/又は治療するための医薬組成物。
- 前記メラノーマが表在拡大型黒色腫、結節性メラノーマ、悪性黒子由来黒色腫、及び末端黒子型黒色腫からなる群から選択される、請求項1に記載の医薬組成物。
- ダパンストリルが全身投与により投与される、請求項1に記載の医薬組成物。
- 前記ダパンストリルが経口投与により投与される、請求項3に記載の医薬組成物。
- 前記医薬組成物がメラノーマの大きさを減少することによりメラノーマを治療する、請求項1に記載の医薬組成物。
- さらに抗PD-1抗体と共に投与される、請求項1に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862645999P | 2018-03-21 | 2018-03-21 | |
US62/645,999 | 2018-03-21 | ||
PCT/US2019/022770 WO2019182981A1 (en) | 2018-03-21 | 2019-03-18 | Methods for treating melanoma |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021518374A JP2021518374A (ja) | 2021-08-02 |
JPWO2019182981A5 JPWO2019182981A5 (ja) | 2022-03-15 |
JP7229565B2 true JP7229565B2 (ja) | 2023-02-28 |
Family
ID=67987925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020550082A Active JP7229565B2 (ja) | 2018-03-21 | 2019-03-18 | メラノーマを治療するための方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11857529B2 (ja) |
EP (1) | EP3768384A4 (ja) |
JP (1) | JP7229565B2 (ja) |
CN (1) | CN111867678B (ja) |
CA (1) | CA3094307A1 (ja) |
MX (1) | MX2020009552A (ja) |
WO (1) | WO2019182981A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210077582A1 (en) * | 2019-09-13 | 2021-03-18 | Duke University | Compositions and methods for increasing the efficacy of anti-pd-1 antibody immunotherapy |
JP2022551672A (ja) * | 2019-10-14 | 2022-12-12 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 乳癌治療法 |
WO2023023649A1 (en) * | 2021-08-19 | 2023-02-23 | Olatec Therapeutics Llc | Method for treating parkinson's disease |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016176504A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
JP2020503358A (ja) | 2017-01-06 | 2020-01-30 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 心血管疾患を治療する方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8476316B2 (en) * | 2010-12-15 | 2013-07-02 | Olatec Industries Llc | 3-methanesulfonylpropionitrile for treating inflammation and pain |
WO2013184586A1 (en) * | 2012-06-05 | 2013-12-12 | Olatec Industries Llc | Method for treating skin inflammatory diseases |
BR112014030288A8 (pt) * | 2012-06-05 | 2021-06-22 | Olatec Ind Llc | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila |
CN113582889A (zh) * | 2015-02-16 | 2021-11-02 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
EP3445761A1 (en) * | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
WO2018129231A1 (en) * | 2017-01-06 | 2018-07-12 | Olatec Therapeutics Llc | Method for treating multiple sclerosis |
US20210254056A1 (en) | 2017-05-05 | 2021-08-19 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
EP3746057B1 (en) * | 2018-01-31 | 2024-03-20 | Olatec Therapeutics, Inc. | Dapansutrile for preventing or treating alzheimer's disease |
-
2019
- 2019-03-18 JP JP2020550082A patent/JP7229565B2/ja active Active
- 2019-03-18 MX MX2020009552A patent/MX2020009552A/es unknown
- 2019-03-18 CA CA3094307A patent/CA3094307A1/en active Pending
- 2019-03-18 WO PCT/US2019/022770 patent/WO2019182981A1/en unknown
- 2019-03-18 CN CN201980020523.3A patent/CN111867678B/zh active Active
- 2019-03-18 EP EP19771591.5A patent/EP3768384A4/en active Pending
-
2020
- 2020-09-15 US US17/021,733 patent/US11857529B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016176504A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
JP2020503358A (ja) | 2017-01-06 | 2020-01-30 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 心血管疾患を治療する方法 |
Non-Patent Citations (2)
Title |
---|
Proceeding of the National Academy of Sciences of the United States of America,2018年01月29日,Vol.115, No.7,p.E1530-E1539 |
Toxicology and Applied Pharmacology,2013年,Vol.279, No.1,p.70-76 |
Also Published As
Publication number | Publication date |
---|---|
MX2020009552A (es) | 2020-10-05 |
CN111867678B (zh) | 2023-04-28 |
CA3094307A1 (en) | 2019-09-26 |
EP3768384A1 (en) | 2021-01-27 |
CN111867678A (zh) | 2020-10-30 |
JP2021518374A (ja) | 2021-08-02 |
US20200405681A1 (en) | 2020-12-31 |
US11857529B2 (en) | 2024-01-02 |
EP3768384A4 (en) | 2021-11-17 |
WO2019182981A1 (en) | 2019-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11857529B2 (en) | Methods for treating melanoma | |
BR112019024135A2 (pt) | Terapias de combinação para o tratamento de câncer | |
Foletto et al. | Cutaneous melanoma: new advances in treatment | |
WO2011069141A2 (en) | Interferon therapies in combination with blockade of stat3 activation | |
CN108139403B (zh) | 用于组合疗法的患者的选择 | |
KR20180094989A (ko) | 노화 관련 인지장애 및 신경염증의 예방 및/또는 치료 방법 | |
CA2962451A1 (en) | Treatment of cancer with immune stimulators | |
US11517575B2 (en) | Use of minaprine to reduce tumor growth | |
Pavia et al. | Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID‐19 vaccine, successfully treated with risankizumab | |
JP2024012493A (ja) | 消化管間質腫瘍の治療のための併用療法 | |
JP2011506436A (ja) | 細胞傷害性tリンパ球抗原4(ctla4)に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
KR101978108B1 (ko) | 암 세포의 대사 특이성에 기초하는 신규 항 악성 종양제 | |
KR20090020646A (ko) | 4기 악성 흑색종의 치료를 위한 약제의 제조를 위한 티모신알파 1의 용도 | |
WO2018083704A1 (en) | Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses | |
JP2018501247A (ja) | 免疫療法による治療および組成物 | |
US20200170990A1 (en) | Method for treating schnitzler's syndrome | |
US20220249425A1 (en) | Methods for treating breast cancer | |
SONE et al. | In vitro cytotoxicity to various human tumor cell lines of a tumor cytotoxic factor (s) produced by human alveolar macrophages | |
JP2020524167A (ja) | Nk−92細胞とil−15アゴニストの併用療法 | |
CN113905764B (zh) | 用于治疗癌症的前体半胱天冬酶-3活化作用和免疫疗法 | |
WO2023168247A1 (en) | Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential | |
JP7303827B2 (ja) | 腫瘍増殖を抑制するためのミナプリンの使用 | |
US20230233474A1 (en) | Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer | |
Fromer | Metastatic Kidney Cancer: Prognosis Still Poor, But New Treatment Options on Horizon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220307 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220307 |
|
TRDD | Decision of grant or rejection written | ||
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221223 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7229565 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |